Primary plasma cell leukemia (pPCL) is a rare and aggressive form of plasma cell dyscrasia and may represent a valid model for high-risk multiple myeloma (MM). To provide novel information concerning the mutational profile of this disease, we performed the whole-exome sequencing of a prospective series of 12 pPCL cases included in a Phase II multicenter clinical trial and previously characterized at clinical and molecular levels. We identified 1, 928 coding somatic non-silent variants on 1, 643 genes, with a mean of 166 variants per sample, and only few variants and genes recurrent in two or more samples. An excess of C > T transitions and the presence of two main mutational signatures (related to APOBEC over-activity and aging) occurring in different translocation groups were observed. We identified 14 candidate cancer driver genes, mainly involved in cell-matrix adhesion, cell cycle, genome stability, RNA metabolism and protein folding. Furthermore, integration of mutation data with copy number alteration profiles evidenced biallelically disrupted genes with potential tumor suppressor functions. Globally, cadherin/Wnt signaling, extracellular matrix and cell cycle checkpoint resulted the most affected functional pathways. Sequencing results were finally combined with gene expression data to better elucidate the biological relevance of mutated genes. This study represents the first whole-exome sequencing screen of pPCL and evidenced a remarkable genetic heterogeneity of mutational patterns. This may provide a contribution to the comprehension of the pathogenetic mechanisms associated with this aggressive form of PC dyscrasia and potentially with high-risk MM.

作者：Ingrid, Cifola；Marta, Lionetti；Eva, Pinatel；Katia, Todoerti；Eleonora, Mangano；Alessandro, Pietrelli；Sonia, Fabris；Laura, Mosca；Vittorio, Simeon；Maria Teresa, Petrucci；Fortunato, Morabito；Massimo, Offidani；Francesco, Di Raimondo；Antonietta, Falcone；Tommaso, Caravita；Cristina, Battaglia；Gianluca, De Bellis；Antonio, Palumbo；Pellegrino, Musto；Antonino, Neri

来源：Oncotarget 2015 年 6卷 19期